Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 30, Issue 2, 2015, Pages 94-99

  Meckel, Marian ^a   Nauth, Alexander ^a   Timpe, Jan ^a   Zhernosekov, Konstantin ^b   Puranik, Ameya D ^c   Baum, Richard P ^c   Rösch, Frank ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b ITM Isotopen Technologien München AG   (Germany)

^c ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

bone metastases; endoradiotherapy

Indexed keywords

ALCOHOL; ANTIMETASTATIC AGENT; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GALLIUM 68; TRACER; UNCLASSIFIED DRUG; [4 [[BIS(PHOSPHONOMETHYL)]CARBAMOYL]METHYL] 7,10 BIS(CARBOXYMETHYL) 1,4,7,10 TETRAAZACYCLODODEC 1 YL LU 177; AMIDE; BPAMD LIGAND; DIAGNOSTIC KIT; LUTETIUM; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE METASTASIS; BONE PAIN; BONE TARGETED ENDORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG SYNTHESIS; GOOD MANUFACTURING PRACTICE; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RADIOLYSIS; THIN LAYER CHROMATOGRAPHY; AGED; BONE; BONE NEOPLASMS; DIAGNOSTIC KIT; MALE; PAIN; PROCEDURES; RADIATION RESPONSE; STAINING;

AGED; AMIDES; BONE AND BONES; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; LUTETIUM; MALE; PAIN; RADIOISOTOPES; RADIOPHARMACEUTICALS; REAGENT KITS, DIAGNOSTIC; STAINING AND LABELING;

EID: 84924561432     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2014.1720     Document Type: Article

References (14)

1. Bodei L, Lam M, Chiesa C, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008; 35: 1934.
2. Kluetz PG, Pierce W, Maher VE, et al. Radium Ra-223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2014; 20: 9.
3. Fellner M, Baum RP, Kubícek V, et al. PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: First human study. Eur J Nucl Med Mol Imaging 2010; 37: 834.
4. Vitha T, Kubícek V, Hermann P, et al. Lanthanide (III) complexes of bis (phosphonate) monoamide analogues of DOTA: Bone-seeking agents for imaging and therapy. J Med Chem 2008; 51: 677.
5. Lebedev NA, Novgorodov AF, Misiak R, et al. Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb (n,c)177Yb/177Lu process. Appl Radiat Isot 2000; 53: 421.
6. Meckel M, Fellner M, Thieme N, et al. In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models. Nucl Med Biol 2013; 40: 823.
7. Fellner M, Biesalski B, Bausbacher N, et al. (68)Ga- BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 2012; 39: 993.
8. Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: On the way to THERANOSTICS. Dalton Trans 2011; 40: 6104.
9. Wadas TJ, Wong EH, Weisman GR, et al. Coordinating radiometals of copper, gallium, indium, yttrium and zirconium for PET and SPECT imaging of disease. Chem Rev 2010; 110: 2858.
10. Pillai MRA, Chakraborty S, Das T, et al. Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot 2003; 59: 109.
11. Delacroix D, Guerre JP, Leblanc P, et al. Radiation Protection Dosimetry-Radionuclide and Radiation Protection Data Handbook. Kent, England: Nuclear Technology Publishing, 1998; 58.
12. Yuan J, Liu C, Liu X, et al. Efficacy and safety of 177Lu- EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: A phase II study. Clin Nucl Med 2013; 38: 88.
13. Shinto AS, Shibu D, Kamaleshwaran KK, et al. 177Lu- EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J Nucl Med Technol 2014; 42: 55.
14. de Blois E, Chan HS, de Zanger R, et al. Application of single-vial ready-for-use formulation of 111In- or 177Lulabelled somatostatin analogs. Appl Radiat Isot 2014; 85: 28.